IRWD — Ironwood Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapTurnaround

Annual income statement for Ironwood Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	414	411	443	351	296
Cost of Revenue
Gross Profit	414	411	—	—	—
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	181	160	1,388	258	198
Operating Profit	232	250	-945	93.1	98.5
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	201	252	-948	65.2	70
Provision for Income Taxes
Net Income After Taxes	528	175	-1,032	0.88	24
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	528	175	-1,002	0.88	24
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	528	180	-1,002	0.88	24
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3.21	0.964	0.676	0.016	0.228